Radiation oncology is not a dying field, but it is a field in transition. The core demand driver, cancer incidence, continues to rise worldwide, and roughly 40% to 60% of all cancer patients need radiation therapy as part of their treatment. An independent workforce analysis commissioned by the American Society for Radiation Oncology (ASTRO) in 2022 projected a relative balance between supply and demand for radiation oncologists through 2030, with growing Medicare enrollment largely absorbing the current workforce. The field faces real pressures from reimbursement cuts, shorter treatment courses, and competition from other treatment modalities, but none of these amount to an existential threat.
Why the Question Keeps Coming Up
The “dying field” narrative gained traction in the mid-2010s when residency applicant interest dipped and several high-profile reimbursement cuts hit radiation oncology practices. Medicare payment rates have continued trending downward: the 2025 Medicare Physician Fee Schedule reduced average payment rates by 2.93% compared to 2024. For a specialty that relies heavily on Medicare-age patients, sustained payment reductions create genuine financial strain on practices, particularly freestanding cancer centers that bill technical fees for equipment use.
At the same time, hypofractionation, delivering radiation in fewer but larger doses, has become the standard of care for several common cancers including breast and prostate. A course that once required 30 daily visits might now take five. Fewer visits per patient means less revenue per case under traditional fee-for-service models, even though the clinical outcomes are as good or better. This shift has forced practices to restructure how they think about patient volume and billing.
The Demand Side Is Growing
Cancer incidence is not slowing down. Population aging alone guarantees rising case numbers for decades. The ASTRO workforce study found that rapid growth in Medicare beneficiaries through 2030 would keep pace with the supply of radiation oncologists entering the workforce. A projection study for Colombia, which mirrors broader global trends, estimated that radiation therapy cases would climb from about 48,500 in 2020 to nearly 73,700 by 2035, a roughly 52% increase in 15 years.
In many parts of the world, radiation therapy access remains far below what patients need. Countries classified as upper-middle-income have roughly 1.1 to 1.6 megavoltage machines per million people, well short of what’s required. Even in the United States, geographic gaps in coverage exist, particularly in rural areas. The global shortfall in radiation infrastructure means the field has significant room to expand internationally, even if domestic growth is more modest.
Immunotherapy Is a Partner, Not a Replacement
One persistent worry is that immunotherapy and other systemic treatments will make radiation obsolete. The reality is closer to the opposite. Immunotherapy is now considered a pillar of cancer treatment alongside surgery, chemotherapy, and radiation, and the most promising research involves combining it with radiation rather than choosing one over the other.
When radiation is delivered to a tumor, it can trigger the release of proteins that help the immune system recognize cancer cells. Pairing stereotactic radiation (precise, high-dose beams) with immune checkpoint inhibitors may improve both local tumor control and the body’s ability to fight cancer elsewhere in the body. Researchers are still working out the best sequencing and how to minimize overlapping side effects, but the trajectory points toward more combination protocols, not fewer radiation referrals.
New Technology Is Expanding What Radiation Can Do
Far from stagnating, radiation oncology is in one of its most active periods of technological development. FLASH radiotherapy, which delivers an entire treatment dose in less than a tenth of a second using ultra-high dose rates, has shown a striking ability to spare healthy tissue while maintaining the same tumor-killing effectiveness as conventional radiation. This “FLASH effect” could dramatically reduce side effects and open the door to treating tumors near sensitive organs that were previously difficult to irradiate safely.
FLASH is still in early clinical testing and requires substantial modifications to existing equipment, but it represents the kind of leap that redefines a specialty rather than shrinking it. MR-guided linear accelerators, which combine real-time MRI imaging with radiation delivery, are already in clinical use and allow treatments to adapt in real time as tumors shift or organs move. Adaptive radiotherapy, where treatment plans are adjusted session by session based on how the tumor is responding, is becoming increasingly practical. These advances make radiation oncologists more essential to multidisciplinary cancer teams, not less.
Residency Match Data Tells a Nuanced Story
The residency match is often cited as evidence of decline. In the 2025 NRMP match, radiation oncology offered 122 positions and filled 118 of them, a 96.7% fill rate. That’s a healthy number by most standards, though it represents a smaller applicant pool than the field saw at its peak competitiveness a decade ago. Fewer applicants per position means less competition, which can reflect reduced student interest, but a near-complete fill rate also shows the specialty is not struggling to attract trainees.
The ASTRO workforce analysis flagged a potential concern beyond 2030: if the growth in new radiation oncologists doesn’t slow to match a projected decline in Medicare beneficiary growth rates, oversupply could become an issue. This suggests the field may need to right-size its training pipeline, but that’s a calibration problem, not a sign of collapse.
What This Means for Career Decisions
If you’re a medical student weighing radiation oncology, the honest picture is a specialty with stable near-term demand, evolving technology, and real financial headwinds. Compensation for radiation oncologists remains among the higher physician specialties, though it has compressed somewhat. Radiation therapists (the technologists who operate the machines) earned a median salary of about $102,000 in 2024, with those in outpatient care centers earning closer to $121,000.
The physicians who thrive in the field going forward will likely be those comfortable with technology, engaged in multidisciplinary collaboration, and willing to adapt as treatment paradigms shift toward shorter courses, combination therapies, and precision techniques. Practice settings are also evolving: hospital-employed positions have grown relative to private practice, changing the day-to-day experience and compensation structure.
The bottom line is that cancer isn’t going away, and radiation remains one of the most effective and cost-efficient tools for treating it. The field is changing in ways that create uncertainty, which is what fuels the “dying field” narrative. But changing and dying are very different things.